Tumor lymphocytic infiltration as a good prognostic factor for survival in patients with locally advanced gastric cancer
Original Research
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 José Castillo, Henry Caballero, Verónica Tapia

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
DOI:
https://doi.org/10.33821/601Keywords:
Stomach Neoplasms, Lymphocytes, Tumor-Infiltrating, Survival Analysis, Survival, Biomarkers, TumorAbstract
Introduction: The relationship between survival and lymphocytic infiltration in gastric cancer has been determined to be a beneficial prognostic factor. This local study aims to assess the probability of survival in patients with gastric cancer stages IB to IIIC according to the percentage of lymphocytic infiltration.
Methodology: This longitudinal study was conducted at the Solón Espinosa Ayala Solca-Núcleo Cancer Hospital in Quito. The study period was from January 2013 to January 2016; the follow-up time ended in December 2018. The sample calculation was nonprobabilistic and included cases of patients older than 18 diagnosed with gastric cancer with clinical stages IB at IIIC, which had a histo-pathological sample of gastrectomies. The variable "percentage of infiltration" was used to analyze the sample, and it was divided into three groups: G1: mild lymphocytic infiltration, G2: moderate, and G3: intense. Survival estimates were calculated using the Kaplan–Meier method and compared groups with the log-rank test.
Results: A total of 173 patients with gastric cancer with clinical stages IB to IIIC were followed up for 72 months; 60% were men, and 40% were women. According to the percentage of lymphocytic infil-tration, 52% reported a rate of mild infiltration, 21% moderate, and 27% intense. At 72 months of follow-up, survival was 31% in G1, 48% in G2, and 77% in G3 (P= 0.001).
Conclusion: The degree of intense lymphocytic infiltration in gastric cancer patients was associated with better survival at the 72-month follow-up.